This is a binary catalyst event — the first patient dosed de-risks the trial start but provides no efficacy signal. Monitor for enrollment updates and preliminary clinical readouts in the near term, which will be the next major value inflection point.
Price Chart
Executive Summary
Silexion Therapeutics announced the first patient has been dosed in its Phase 2/3 clinical trial of SIL204 for locally advanced pancreatic cancer. This is a binary clinical milestone for a pre-revenue biotech, transitioning the lead RNAi candidate into active patient treatment, but no efficacy or safety data were released.
Key Facts
- First patient dosed globally in Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer (LAPC).
- Trial is a prospective, randomized, controlled, multinational, open-label study.
- Initial safety run-in cohort of approximately 18 patients, followed by randomized cohort of approximately 166 patients.
- SIL204 is a second-generation siRNA targeting KRAS-driven cancers, administered via dual-route delivery (intratumoral EUS-guided + subcutaneous).
- First patient treated at Tel Aviv Sourasky Medical Center (Ichilov) in Israel.
- Additional sites in Israel and Germany are progressing through activation.
Financial Impact
No financial data provided in the filing; clinical-stage biotech with no revenue.
Risk Factors
- No efficacy or safety data released; early dosing does not predict trial success.
- Enrollment risk — the trial requires ~184 patients across multiple sites in Israel and Germany.
- Pre-revenue company with potential financing needs to complete the trial.
- KRAS-driven pancreatic cancer is a historically difficult target with high failure rates.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001178913-26-004666 |
| Exhibit: exhibit_99-1.htm | 0001178913-26-004666 |
| Document: 0001178913-26-004666-index-headers.html | 0001178913-26-004666 |
| Document: 0001178913-26-004666-index.html | 0001178913-26-004666 |
| Document: 0001178913-26-004666.txt | 0001178913-26-004666 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEFA14A | $0.1538 | awaiting T+20 | — | $0.1733 (−12.68%) |
Oct 5, 2026 21d ago | DEF 14A | $0.2628 | awaiting T+20 | — | $0.1733 (+34.06%) |
Sep 30, 2026 27d ago | 8-K | $0.2770 | awaiting T+20 | — | $0.1733 (−37.44%) |
Sep 30, 2026 27d ago | Press Release | $0.2773 | awaiting T+20 | — | $0.1733 (+37.50%) |
Sep 29, 2026 28d ago | 8-K | $0.3180 | awaiting T+20 | — | $0.1733 (+45.50%) |
Sep 29, 2026 28d ago | Press Release | $0.3184 | awaiting T+20 | — | $0.1733 (+45.57%) |
Sep 28, 2026 29d ago | 8-K | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1733 (−30.23%) |
Sep 28, 2026 29d ago | Press Release | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1733 (−30.23%) |
Sep 25, 2026 4w ago | 8-K | $0.2484 $0.1746 | ▲ +29.71% | ▲ +29.68% | $0.1733 (+30.23%) |
Aug 14, 2026 10w ago | 8-K | $0.4202 $0.3854 | ▲ +8.28% | ▲ +6.29% | $0.1733 (+58.76%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers